Impact of Impulsivity, Hyperactivity, and Inattention on Discontinuation Rate among Opioid-Dependent Patients Treated with Extended-Release Naltrexone.
extended-release naltrexone
impulsivity
retention in treatment
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
11 09 2022
11 09 2022
Historique:
received:
07
07
2022
revised:
07
09
2022
accepted:
08
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
Previous studies have indicated elevated levels of impulsivity, hyperactivity, and inattention (IHI) among opioid-dependent patients seeking outpatient treatment with extended-release naltrexone (XR-NTX). This led us to hypothesize that IHI may be associated with a higher discontinuation rate for XR-NTX treatment. In a group of 162 patients with opioid dependence, discontinuation prior to the full 24 weeks of the study period (six injections and attending the study visit at 24 weeks) occurred in 49% of the patients, primarily in the early stage of treatment. IHI above the clinical cut-off on the adult ADHD self-report scale (ASRS) was not associated with a risk of premature discontinuation. This finding was not altered when controlling for socio-demographics, substance, use and mental health severity. Conclusively, high levels of IHI per se is not contradictive for XR-NTX treatment in regard to concern for premature discontinuation.
Identifiants
pubmed: 36141709
pii: ijerph191811435
doi: 10.3390/ijerph191811435
pmc: PMC9517108
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Delayed-Action Preparations
0
Narcotic Antagonists
0
Naltrexone
5S6W795CQM
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare that they have no competing interest.
Références
J Clin Med. 2021 Sep 30;10(19):
pubmed: 34640572
Eur Addict Res. 2019;25(6):303-309
pubmed: 31340204
JAMA Psychiatry. 2017 Dec 1;74(12):1197-1205
pubmed: 29049469
J Addict Med. 2019 Mar/Apr;13(2):93-103
pubmed: 30531584
J Subst Abuse Treat. 2022 May;136:108667
pubmed: 34865937
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
J Subst Abuse Treat. 2022 May;136:108686
pubmed: 34953637
Nord J Psychiatry. 2003;57(2):113-8
pubmed: 12745773
Am J Addict. 2017 Jun;26(4):319-325
pubmed: 28328148
Contemp Clin Trials Commun. 2021 Feb 10;21:100728
pubmed: 33665469
J Subst Abuse Treat. 2021 Mar;122:108183
pubmed: 33162260
Addict Behav. 2014 Oct;39(10):1504-9
pubmed: 24960556
J Subst Abuse Treat. 2018 Feb;85:90-96
pubmed: 28733097
Clin Psychol Rev. 2013 Dec;33(8):1010-24
pubmed: 24029221
CNS Drugs. 2013 Oct;27(10):851-61
pubmed: 24018540
Psychol Med. 2005 Feb;35(2):245-56
pubmed: 15841682
Addict Biol. 2007 Jun;12(2):176-82
pubmed: 17508990
Drug Alcohol Depend. 2019 Jul 1;200:34-39
pubmed: 31082666
Addiction. 2018 Jul;113(7):1188-1209
pubmed: 29396985
Drug Alcohol Depend. 2018 Jun 1;187:22-28
pubmed: 29626742
Am J Drug Alcohol Abuse. 2012 May;38(3):187-99
pubmed: 22404717
Sci Pract Perspect. 2002 Jul;1(1):13-20
pubmed: 18567959
Am J Addict. 2020 Jul;29(4):249-267
pubmed: 32346932
JAMA. 2000 Oct 4;284(13):1689-95
pubmed: 11015800